Literature DB >> 4050826

Glomerular mesangium: its function and relationship to angiotensin II.

L Raij, W F Keane.   

Abstract

The glomerular mesangium is composed of mesangial cells and an intercellular material, the mesangial matrix. Partly because of its unique anatomic location, the mesangium appears to be susceptible to immune- and non-immune-mediated injury. Mesangial cells have characteristics similar to smooth muscle cells, and their surface is covered with receptors that bind a variety of vasoactive substances. The glomerular mesangium seems to play an important role in the physiologic regulation of the glomerular microcirculation. There is evidence that a plasmic flow carrying macromolecules circulates through the mesangium. Changes in glomerular hemodynamic determinants and in the release and/or production of vasoactive substances, particularly angiotensin II, can greatly influence the mesangial movement of macromolecules. Quantitative and/or qualitative alterations in the mesangial movement of macromolecules may lead to mesangial injury.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4050826     DOI: 10.1016/0002-9343(85)90076-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.

Authors:  O Samuelsson; T Hedner; S Ljungman; H Herlitz; B Widgren; K Pennert
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Effects of enalapril on renal parameters in patients with primary glomerulopathies associated with chronic renal failure.

Authors:  L F Ferder; F Inserra; H Daccordi; L Romano; A Fernández; J Tessler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Dihydropyridine calcium channel blockers and renal disease.

Authors:  Nicolás R Robles; Francesco Fici; Guido Grassi
Journal:  Hypertens Res       Date:  2016-07-14       Impact factor: 3.872

Review 4.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

5.  The pathogenesis and prevention of diabetic nephropathy.

Authors:  R Omachi
Journal:  West J Med       Date:  1986-08

Review 6.  ACE inhibitors and diabetic nephropathy: clinical and experimental findings.

Authors:  C Hasslacher; H P Kempe; A Bostedt-Kiesel
Journal:  Clin Investig       Date:  1993

7.  Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect.

Authors:  S Rudberg; A Aperia; U Freyschuss; B Persson
Journal:  Diabetologia       Date:  1990-08       Impact factor: 10.122

8.  Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.

Authors:  C Rangemark; H Lind; L Lindholm; T Hedner; O Samuelsson
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 9.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

10.  Renal protective effect of long term antihypertensive therapy with enalapril.

Authors:  J H Bauer; G P Reams
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.